Disease · MONDO_0005512

malignant peritoneal mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant peritoneal mesothelioma. Diseases, record MONDO_0005512. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005512

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant peritoneal mesothelioma; Open Targets
Open Targets ID: MONDO_0005512; Open Targets
Other names: advanced malignant mesothelioma of peritoneum, advanced malignant mesothelioma of the peritoneum, advanced malignant peritoneal mesothelioma, advanced peritoneal malignant mesothelioma, diffuse malignant peritoneal mesothelioma, malignant mesothelioma (disease) of peritoneum, malignant mesothelioma of peritoneum, malignant peritoneal mesothelioma, advanced, peritoneal mesothelioma (disease), malignant, peritoneum malignant mesothelioma (disease), primary malignant peritoneal mesothelioma; Open Targets
Disease Ontology: DOID:1788; Disease Ontology
NCI Thesaurus: C8704; NCI Thesaurus
Orphanet: ORPHA:168811; Orphanet
Highest stage of its drugs: Phase 2, for 10 of its 16 drugs, from ClinicalTrials.gov; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERLOTINIB HYDROCHLORIDE	CHEMBL1079742	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TALAZOPARIB	CHEMBL3137320	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 2	https://conductscience.org/library/genes/2618	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3455	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Unknown	https://conductscience.org/library/genes/3791	Drugs and targets
PARP1	Poly [ADP-ribose] polymerase 1	1	Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	Poly [ADP-ribose] polymerase 2	1	Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/10038	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02151448	αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies	Phase 1/2	64	2020-01-28	Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis	CELECOXIB, INTERFERON ALFA-2B, RINTATOLIMOD	Its record names the disease	ClinicalTrials.gov
NCT00859469	Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma	Phase 2	29	2012-02-24	Mesothelioma	GEMCITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01592383	Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma	Phase 2	2	2018-10-16	Malignant Peritoneal Mesothelioma	ERLOTINIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT07330271	PTC-Guided Therapy for Peritoneal Mesothelioma	Not applicable	347		Peritoneal Mesothelioma	GEMCITABINE, OXALIPLATIN, RIVOCERANIB	Its record names the disease	ClinicalTrials.gov
NCT03875144	Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)	Phase 2	66		Peritoneal Mesothelioma, Peritoneal Carcinomatosis	CISPLATIN, DOXORUBICIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT06057935	A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2	64		Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma	CARBOPLATIN, CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT03834948	AO-176 in Multiple Solid Tumor Malignancies	Phase 1/2	57		Solid Tumor	PACLITAXEL, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04462809	Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma	Phase 2	40		Advanced Malignant Pleural or Peritoneal Mesothelioma	TALAZOPARIB	Its record names the disease	ClinicalTrials.gov
NCT06543069	Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM	Phase 2	28		Malignant Peritoneal Mesothelioma, Advanced	BEVACIZUMAB, CISPLATIN, PEMETREXED, SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT05449366	Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma	Phase 1/2	7		Peritoneal Malignant Mesothelioma	PACLITAXEL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
33431660	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005512

GET https://conductscience.org/api/diseases/v1/MONDO_0005512/targets?page=2

API reference For AI assistants